Acquired hemophilia A

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 7, 2012, Pages 735-741

  Webert, Kathryne ^a,b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

acquired hemophilia A; bleeding; inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DESMOPRESSIN ACETATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; VINCRISTINE;

ACQUIRED HEMOPHILIA A; ARTICLE; BLEEDING; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; FOLLOW UP; HEMATOMA; HEMOPHILIA A; HUMAN; IMMUNOADSORPTION; INCIDENCE; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; SKIN BRUISING;

ANIMALS; HEMOPHILIA A; HUMANS; SWINE;

EID: 84872100138     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1326779     Document Type: Article

References (86)

1. Collins P., Macartney N., Davies R., Lees S., Giddings J., Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol: 2004; 124 1 86 90
2. Knoebl P., Marco P., Baudo F., et al. EACH2 Registry Contributors Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost: 2012; 10 4 622 631
3. Cohen A. J., Kessler C. M. Acquired inhibitors. Baillieres Clin Haematol: 1996; 9 2 331 354
4. Green D., Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost: 1981; 45 3 200 203
5. Yee T. T., Pasi K. J., Lilley P. A., Lee C. A. Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. Br J Haematol: 1999; 104 4 909 914
6. Franchini M., Zaffanello M., Lippi G. Acquired hemophilia in pediatrics: a systematic review. Pediatr Blood Cancer: 2010; 55 4 606 611
7. Franchini M., Gandini G., Di Paolantonio T., Mariani G. Acquired hemophilia A: a concise review. Am J Hematol: 2005; 80 1 55 63
8. Collins P. W., Hirsch S., Baglin T. P., et al. UK Haemophilia Centre Doctors' Organisation Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood: 2007; 109 5 1870 1877
9. The Association of Hemophilia Clinic Directors of Canada (AHCDC) A guide to the management of patients with inhibitors to factor VIII and factor IX. Toronto, Ontario, Canada: AHCDC; 2010. Available at: www.ahcdc.ca/documents/ InhibitorGuide2010.pdf. Last accessed April 25, 2012
10. Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol: 2006; 81 10 768 773
11. Biggs R., Austen D. E., Denson K. W., Rizza C. R., Borrett R. The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs. Br J Haematol: 1972; 23 2 125 135
12. Ma A. D., Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology (Am Soc Hematol Educ Program): 2006; 432 437
13. Franchini M., Targher G., Montagnana M., Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta: 2008; 395 1-2 14 18
14. Huth-Kühne A., Baudo F., Collins P., et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica: 2009; 94 4 566 575
15. Kasper C. K., Aledort L., Aronson D., et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh: 1975; 34 2 612
16. Verbruggen B., Novakova I., Wessels H., Boezeman J., van den Berg M., Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost: 1995; 73 2 247 251
17. Gawryl M. S., Hoyer L. W. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood: 1982; 60 5 1103 1109
18. Martin P. G., Sukhu K., Chambers E., Giangrande P. L. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol: 1999; 21 2 125 128
19. Sahud M., Zhukov O., Mo K., Popov J., Dlott J. False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies. Haemophilia: 2012;; Epub ahead of print. doi: 10.111/j.1356-2516.2012.02781.x
20. Collins P., Baudo F., Huth-Kühne A., et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes: 2010; 3 161
21. Collins P. W. Management of acquired haemophilia A. J Thromb Haemost: 2011; 9 Suppl 1 226 235
22. Lottenberg R., Kentro T. B., Kitchens C. S. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med: 1987; 147 6 1077 1081
23. FEIBA NF Anti-Inhibitor Coagulant Complex Product monograph. Vienna, Austria; Baxter AG; 2011. Available at: www.baxter.ca/en/downloads/product- information/feiba-pm-en-070511.pdf. Last accessed April 25, 2012
24. NiaStase RT Product monograph. Mississauga, Ontario, Canada; Novo Nordisk Canada, Inc.; 2010. Available at: www.novonordisk.ca/PDF-files/ NiaStaseRTPMEnglish-2010-03-18.pdf. Last accessed April 25, 2012
25. Sjamsoedin L. J., Heijnen L., Mauser-Bunschoten E. P., et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med: 1981; 305 13 717 721
26. Hilgartner M. W., Knatterud G. L. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood: 1983; 61 1 36 40
27. Sultan Y., Loyer F. In vitro evaluation of factor VIII-bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors: thrombin generation test in the presence of collagen-activated platelets. J Lab Clin Med: 1993; 121 3 444 452
28. Barthels M. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors. Thromb Res: 1999; 95 4, Suppl 1 S31 S38
29. Roberts H. R. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia. Vox Sang: 1999; 77 Suppl 1 38 41
30. Leissinger C. A. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia: 1999; 5 Suppl 3 25 32
31. Abshire T. Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia. Semin Hematol: 2008; 45 2, Suppl 1 S3 S6
32. Hedner U., Glazer S., Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev: 1993; 7 2 78 83
33. Papadaki H. A., Xylouri I., Valatas W., Petinarakis J., Kontopoulou I., Eliopoulos G. D. Severe acquired hemophilia A successfully treated with activated recombinant human factor VII. Ann Hematol: 1998; 77 3 123 125
34. Hay C. R., Ollier W., Pepper L., et al. UKHCDO Inhibitor Working Party HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost: 1997; 77 2 234 237
35. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost: 1999; 82 2 531 539
36. Ingerslev J., Sneppen O., Hvid I., Fredberg U., Kristensen H. L., Sindet-Petersen S. Treatment of acute bleeding episodes with rFVIIa. Vox Sang: 1999; 77 Suppl 1 42 46
37. Ingerslev J., Christiansen K., Calatzis A., Holm M., Sabroe Ebbesen L. Management and monitoring of recombinant activated factor VII. Blood Coagul Fibrinolysis: 2000; 11 Suppl 1 S25 S30
38. Liebman H. A., Chediak J., Fink K. I., Galvez A. G., Shah P. C., Sham R. L. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol: 2000; 63 3 109 113
39. Jurlander B., Thim L., Klausen N. K., et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost: 2001; 27 4 373 384
40. Hedner U., Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion: 2002; 42 1 114 124
41. Sumner M. J., Geldziler B. D., Pedersen M., Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia: 2007; 13 5 451 461
42. Kessler C. M., Ludlam C. A.; International Acquired Hemophilia Study Group. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. Semin Hematol: 1993; 30 2, Suppl 1 22 27
43. Hay C. R., Bolton-Maggs P. Porcine factor VIIIC in the management of patients with factor VIII inhibitors. Transfus Med Rev: 1991; 5 4 293 299
44. Gatti L., Mannucci P. M. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemost: 1984; 51 3 379 384
45. Kernoff P. BA, Thomas N. D., Lilley P. A., Matthews K. B., Goldman E., Tuddenham E. G. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood: 1984; 63 1 31 41
46. Brettler D. B., Forsberg A. D., Levine P. H., et al. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med: 1989; 149 6 1381 1385
47. Hay C. RM. Innovative use of porcine factor VIII:C for immune tolerance induction. Am J Med: 1991; 91 5A 27S 29S
48. Franchini M., Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus: 2011; 9 4 377 382
49. Francis J. D., Leary T., Niblett D. J. Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline haemophilia. Acta Anaesthesiol Scand: 1999; 43 8 870 873
50. Bertholini D. M., Butler C. S. Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease. Anaesth Intensive Care: 2000; 28 2 199 201
51. Sunagawa T., Uezu Y., Kadena K., Tokuyama K., Kinjo F., Saito A. Successful treatment of a non-haemophilic patient with inhibitor to factor VIII by double-filtration plasmapheresis. Br J Haematol: 1999; 104 3 465 467
52. Jansen M., Schmaldienst S., Banyai S., et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol: 2001; 112 1 91 97
53. Ogata H., Sakai S., Koiwa F., et al. Plasma exchange for acquired hemophilia: a case report. Ther Apher: 1999; 3 4 320 322
54. Rivard G. E., St Louis J., Lacroix S., Champagne M., Rock G. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia: 2003; 9 6 711 716
55. Seibert F. S., Zidek W., Westhoff T. H. Refractory acquired hemophilia: successful treatment by immunoadsorption with single-use columns. Ther Apher Dial: 2011; 15 3 336 337
56. Guillet B., Kriaa F., Huysse M. G., et al. Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia. Br J Haematol: 2001; 114 4 837 844
57. Collins P., Baudo F., Knoebl P., et al. Immunosuppression for acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2). Blood: 2012;; Epub ahead of print. doi 10.1182/blood-2012-02-409185
58. Green D., Rademaker A. W., Briët E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost: 1993; 70 5 753 757
59. Green D. Oral immunosuppressive therapy for acquired hemophilia. Ann Intern Med: 1998; 128 4 325
60. Shaffer L. G., Phillips M. D. Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med: 1997; 127 3 206 209
61. Reff M. E., Carner K., Chambers K. S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood: 1994; 83 2 435 445
62. Byrd J. C., Kitada S., Flinn I. W., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood: 2002; 99 3 1038 1043
63. Aggarwal A., Grewal R., Green R. J., et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia: 2005; 11 1 13 19
64. Boles J. C., Key N. S., Kasthuri R., Ma A. D. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost: 2011; 9 7 1429 1431
65. Stasi R., Brunetti M., Stipa E., Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood: 2004; 103 12 4424 4428
66. Wiestner A., Cho H. J., Asch A. S., et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood: 2002; 100 9 3426 3428
67. Kain S., Copeland T. S., Leahy M. F. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol: 2002; 119 2 578
68. Abdallah A., Coghlan D. W., Duncan E. M., Chunilal S. D., Lloyd J. V. Rituximab-induced long-term remission in patients with refractory acquired hemophilia. J Thromb Haemost: 2005; 3 11 2589 2590
69. Jy W., Gagliano-DeCesare T., Kett D. H., et al. Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab. Acta Haematol: 2003; 109 4 206 208
70. Holme P. A., Brosstad F., Tjonnfjord G. E. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia: 2005; 11 5 510 515
71. Söhngen D., Specker C., Bach D., et al. Acquired factor VIII inhibitors in nonhemophilic patients. Ann Hematol: 1997; 74 2 89 93
72. Lian E. C., Larcada A. F., Chiu A. Y. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med: 1989; 110 10 774 778
73. Eisert S., Mosler K., Laws H. J., Göbel U. Successful use of mycophenolate mofetil and prednisone in a 14-year-old girl with acquired hemophilia A. Thromb Haemost: 2005; 93 4 792 793
74. Schulman S., Langevitz P., Livneh A., Mortinowitz U., Seligsohn U., Varon D. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost: 1996; 76 3 344 346
75. Brox A. G., Laryea H., Pelletier M. Successful treatment of acquired factor VIII inhibitors with cyclosporin. Am J Hematol: 1998; 57 1 87 88
76. Petrovic M., Derom E., Baele G. Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. Haematologica: 2000; 85 8 895 896
77. Saxena R., Mishra D. K., Kashyap R., Choudhry V. P., Mahapatra M., Bhargava M. Acquired haemophilia - a study of ten cases. Haemophilia: 2000; 6 2 78 83
78. Franchini M., Lippi G. Acquired factor VIII inhibitors. Blood: 2008; 112 2 250 255
79. Collins P. W. Treatment of acquired hemophilia A. J Thromb Haemost: 2007; 5 5 893 900
80. Shurafa M., Raman S., Wollner I. Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma. Am J Hematol: 1995; 50 2 149 150
81. Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Hematol: 1998; 59 1 1 4
82. Baudo F., de Cataldo F.; Italian Association of Haemophilia Centres (AICE): Register of acquired factor VIII inhibitors (RIIA). Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG: 2003; 110 3 311 314
83. Kessler C. M., Acs P., Mariani G. Hemostasis and thrombosis: basic principles and clinical practice. In: Colman R. W., Marder V. J., Clowes A. W., George J. N., Goldhaber S. Z., eds. LWW Medical Book Collection. 5th ed. Philadelphia, PA Lippincott Williams & Wilkins: 2006; 1061 1084
84. Hauser I., Schneider B., Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost: 1995; 73 1 1 5
85. Delgado J., Jimenez-Yuste V., Hernandez-Navarro F., Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol: 2003; 121 1 21 35
86. Tagariello G., Sartori R., Radossi P., Gandini G., Franchini M. Intensive blood transfusion support in acquired hemophilia A. Ann Hematol: 2007; 86 3 229 230